NAS:BGNE (Cayman Islands) Also trade in: Germany Hongkong

BeiGene Ltd

$ 120.32 -1.06 (-0.87%)
Volume: 215,662 Avg Vol (1m): 304,739
Market Cap $: 7.24 Bil Enterprise Value $: 5.88 Bil
P/E (TTM): 0.00 P/B: 4.47
Earnings Power Value -128.85
Net Current Asset Value 20.64
Tangible Book 26.82
Projected FCF 0
Median P/S Value 152.71
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 6.68
Cash-To-Debt ranked lower than
59.65% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
BGNE: 6.68
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.14, Med: 7.55, Max: 39.79
Current: 6.68
0.14
39.79
Equity-to-Asset 0.74
Equity-to-Asset ranked higher than
55.96% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
BGNE: 0.74
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.48, Med: 0.74, Max: 0.92
Current: 0.74
-0.48
0.92
Debt-to-Equity 0.15
Debt-to-Equity ranked higher than
62.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
BGNE: 0.15
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.71, Med: 0.12, Max: 0.6
Current: 0.15
-0.71
0.6
Debt-to-EBITDA -0.32
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
BGNE: -0.32
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -8.7, Med: -0.68, Max: -0.15
Current: -0.32
-8.7
-0.15
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.02
DISTRESS
GREY
SAFE
Beneish M-Score -0.76
Not Manipulator
Manipulator

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -315.55
Operating Margin ranked higher than
53.79% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
BGNE: -315.55
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -10940.19, Med: -238.47, Max: -41.3
Current: -315.55
-10940.19
-41.3
Net Margin % -302.45
Net Margin ranked higher than
54.67% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
BGNE: -302.45
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -11141.78, Med: -240.07, Max: -39.06
Current: -302.45
-11141.78
-39.06
ROE % -46.76
ROE ranked higher than
58.34% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
BGNE: -46.76
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -114.09, Med: -55.89, Max: -18.25
Current: -46.76
-114.09
-18.25
ROA % -36.13
ROA ranked higher than
62.08% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
BGNE: -36.13
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -67.02, Med: -50.76, Max: -12.85
Current: -36.13
-67.02
-12.85
ROC (Joel Greenblatt) % -537.20
ROC (Joel Greenblatt) ranked higher than
53.38% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
BGNE: -537.2
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -904.62, Med: -376.08, Max: -67.2
Current: -537.2
-904.62
-67.2
3-Year Total Revenue Growth Rate 183.10
3-Year Revenue Growth Rate ranked higher than
95.24% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
BGNE: 134.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -45, Med: 134.4, Max: 185.1
Current: 134.4
-45
185.1
3-Year Total EBITDA Growth Rate -133.40
3-Year EBITDA Growth Rate ranked lower than
88.53% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
BGNE: -93.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -294.7, Med: -103.1, Max: -93.3
Current: -93.3
-294.7
-93.3

» BGNE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BGNE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:SAGE NAS:NBIX NAS:EXEL NAS:SGEN XKRX:215600 NAS:IONS TSE:4587 NAS:TECH HKSE:01530 HKSE:01548 NAS:ALKS BOM:532523 XKRX:128940 NAS:SRPT NAS:JAZZ NAS:BLUE SZSE:000661 NAS:AGIO OSTO:SOBI NAS:UTHR
Traded in other countries 49BA.Germany 06160.Hongkong
Address c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a United States based clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.

Ratios

Current vs industry vs history
PB Ratio 4.47
PB Ratio ranked lower than
71.10% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
BGNE: 4.47
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3.19, Med: 4.6, Max: 5.35
Current: 4.47
3.19
5.35
PS Ratio 28.53
PS Ratio ranked lower than
64.05% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
BGNE: 28.53
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 28.24, Med: 36.24, Max: 58.56
Current: 28.53
28.24
58.56
EV-to-EBIT -7.64
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
BGNE: -7.64
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -15.2, Med: -8.95, Max: -7.5
Current: -7.64
-15.2
-7.5
EV-to-EBITDA -7.75
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
BGNE: -7.75
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -15.5, Med: -9.15, Max: -7.6
Current: -7.75
-15.5
-7.6
EV-to-Revenue 24.08
EV-to-Revenue ranked higher than
99.61% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
BGNE: 24.08
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 23.6, Med: 30.75, Max: 51.1
Current: 24.08
23.6
51.1
Current Ratio 7.52
Current Ratio ranked higher than
70.48% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
BGNE: 7.52
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.14, Med: 7.71, Max: 15.91
Current: 7.52
0.14
15.91
Quick Ratio 7.47
Quick Ratio ranked higher than
70.95% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
BGNE: 7.47
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.14, Med: 7.65, Max: 15.91
Current: 7.47
0.14
15.91
Days Inventory 5.83
Days Inventory ranked lower than
55.72% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
BGNE: 5.83
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 5.83, Med: 7.14, Max: 7.28
Current: 5.83
5.83
7.28
Days Sales Outstanding 88.52
Days Sales Outstanding ranked higher than
73.65% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
BGNE: 88.52
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 45.06, Med: 60.33, Max: 88.52
Current: 88.52
45.06
88.52
Days Payable 48.92
Days Payable ranked lower than
98.88% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
BGNE: 48.92
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 44.52, Med: 56.1, Max: 92.96
Current: 48.92
44.52
92.96

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -20.70
3-Year Share Buyback Rate ranked lower than
67.91% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
BGNE: -20.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -20.7, Med: 4.7, Max: 9
Current: -20.7
-20.7
9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.49
Price-to-Tangible-Book ranked lower than
64.09% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
BGNE: 4.49
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 4.46, Med: 4.8, Max: 5.24
Current: 4.49
4.46
5.24
Price-to-Median-PS-Value 0.79
Price-to-Median-PS-Value ranked higher than
90.41% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
BGNE: 0.79
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.78, Med: 1.08, Max: 1.61
Current: 0.79
0.78
1.61
Earnings Yield (Joel Greenblatt) % -13.13
Earnings Yield (Greenblatt) ranked lower than
97.78% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
BGNE: -13.13
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -13.3, Med: -11.15, Max: -6.6
Current: -13.13
-13.3
-6.6

More Statistics

Revenue (TTM) (Mil) $ 243.51
EPS (TTM) $ -12.74
Beta 1.3
Volatility % 51.58
52-Week Range $ 105.19 - 194.56
Shares Outstanding (Mil) 59.81

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N